Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
---|
11/15/2007 | WO2007094000A3 Applications of microencapsulated essential oils |
11/15/2007 | WO2007086536A3 Soft-gelatin capsule formulation |
11/15/2007 | WO2007079390A3 Medicament for topical use |
11/15/2007 | WO2007070504A3 Stable and palatable oral liquid sumatriptan compositions |
11/15/2007 | WO2007066150A3 Transdermal administration of active agents for systemic effect |
11/15/2007 | WO2007063034A3 Base material for producing food and fodder |
11/15/2007 | WO2007047607A3 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues |
11/15/2007 | WO2007043057A3 Compositions for nasal delivery |
11/15/2007 | WO2007036646A3 Injectable viscous medicinal preparation comprising ethanol and an x-ray opaque fat-soluble compound |
11/15/2007 | WO2007022356A3 Drug-surfactant complexes for sustained release |
11/15/2007 | WO2007022149A3 Non-woven scaffold for tissue engineering |
11/15/2007 | WO2006119498A3 Pharmaceutical compositions with synchronized solubilizer release |
11/15/2007 | WO2006100075A8 Use of an artificial sweetener to enhance absorption of nicotine |
11/15/2007 | WO2006094737A8 Gastroresistant pharmaceutical formulations containing rifaximin |
11/15/2007 | WO2006089537A8 Method for production of a preparation of a solid dmso-containing silicone oil emulsion for the binding of reactive oxygen compounds in human and animal bodies |
11/15/2007 | WO2006031833A3 Ultra-violet inhibition system |
11/15/2007 | WO2005118702A3 Unagglomerated core/shell nanocomposite particles |
11/15/2007 | WO2005046572A3 Targeted delivery of controlled release polymer systems |
11/15/2007 | WO2003086313A3 Methods for lightening skin and hair |
11/15/2007 | WO2002019842A3 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
11/15/2007 | US20070265599 Optic nerve head implant and medication delivery system |
11/15/2007 | US20070265598 Device and Method for Treating Weight Disorders |
11/15/2007 | US20070265357 Systems for Preparing Fine Articles and Other Substances |
11/15/2007 | US20070265337 Method and composition for delivering zinc to the nasal membrane |
11/15/2007 | US20070265336 Application of L-N-Butylphthalide in Preventing and Treating Dementia |
11/15/2007 | US20070265207 Treating nocturia, primary nocturnal enuresis, or incontinence, or for inducing voiding postponement; a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum |
11/15/2007 | US20070265194 Agents for the treatment of viral infections |
11/15/2007 | US20070265192 Telechelic Homopolyamino Acids Functionalized with Hydrophobic Groups, and Their Applications, Especially Therapeutic Applications |
11/15/2007 | US20070265190 Opioid depot formulations |
11/15/2007 | US20070264359 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus |
11/15/2007 | US20070264351 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
11/15/2007 | US20070264350 Water-insoluble medicine |
11/15/2007 | US20070264349 Nano-structured compositions and methods of making and using the same |
11/15/2007 | US20070264348 Nanoparticulate fibrate formulations |
11/15/2007 | US20070264346 Multimicroparticulate pharmaceutical forms for oral administration |
11/15/2007 | US20070264345 liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, 26.7-40.0%, propylene-glycol, 13.3-20.0%, isopropyl myristate, 5.0-35.0%, ethanol, 0.01-10.0%, benzyl alcohol, 0.5-1.5%, a hyaluronic acid salt or complex 0.01-2.00%, and purified water, 12.5-26.5%; healing cosmetics |
11/15/2007 | US20070264344 Topically applicable anti-inflammatory O/W emulsions comprising pro-penetrating glycols |
11/15/2007 | US20070264343 Methods for making and using particulate pharmaceutical formulations for sustained release |
11/15/2007 | US20070264342 Solvating system and sealant for medical use in the sinuses and nasal passages |
11/15/2007 | US20070264341 Process of preparing microspheres for sustained release having improved dispersibility and syringeability |
11/15/2007 | US20070264339 Base-stabilized polyorthoester formulations |
11/15/2007 | US20070264338 Base-stabilized polyorthoester formulations |
11/15/2007 | US20070264337 Compositions and methods for the induction and maintenance of quality sleep |
11/15/2007 | US20070264336 Hydrophilic/lipophilic polymeric matrix dosage formulation |
11/15/2007 | US20070264335 Modified release tablets comprising tramadol |
11/15/2007 | US20070264334 Modified release formulation of fenofibric acid in a hydroxypropyl methylcellulose matrix; in vitro dissolution is substantially independent of the dissolution media ionic strength |
11/15/2007 | US20070264333 Method of treatment |
11/15/2007 | US20070264332 Sustained Release Pharmaceutical Formulation |
11/15/2007 | US20070264331 Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin |
11/15/2007 | US20070264330 Pharmaceutical formulations of pimavanserin |
11/15/2007 | US20070264329 Calcium compositions |
11/15/2007 | US20070264328 Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets |
11/15/2007 | US20070264327 Analgesically effective amount of opioid analgesic is combined with gel forming polymer to form a matrix, a surfactant to cause mucosal tissue irritation, and an emetic to cause emesis if greater than a prescribed amount of the analgesic included |
11/15/2007 | US20070264326 Anti-misuse oral microparticle medicinal formulation |
11/15/2007 | US20070264325 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
11/15/2007 | US20070264324 Use of Vegetable Anthraquinone Derivatives and Vegetable Polysaccharides For Treating Human Immunodeficiency Virus (HIV) |
11/15/2007 | US20070264323 Controlled dose drug delivery system |
11/15/2007 | US20070264322 Method for making liposomes conjugated with temperature-sensitive ligands |
11/15/2007 | US20070264321 Method of treating skin wounds with vectors encoding hepatocyte growth factor |
11/15/2007 | US20070264320 Microfluidic device for forming monodisperse lipoplexes |
11/15/2007 | US20070264319 Transdermal Antiemesis Delivery System, Method and Composition Therefor |
11/15/2007 | US20070264317 Imiquimod cream formulation |
11/15/2007 | US20070264316 Patch Activated In Use |
11/15/2007 | US20070264293 Encapsulated Fluorescent Whitening Compositions and Their Use in Personal Care Applications |
11/15/2007 | US20070264290 Pharmaceutical and/or Cosmetic Care Product, Such as a Mask |
11/15/2007 | US20070264289 Compositions and methods of administering doxepin to mucosal tissue |
11/15/2007 | US20070264247 Use of Human Lysozyme in Preparation of Medicine for Treating Acne |
11/15/2007 | US20070264212 Skin Lightening Method |
11/15/2007 | US20070264205 reducing the formation of cellulite in skin by topically applying to the skin a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate |
11/15/2007 | US20070264203 Active particle-enhanced membrane and methods for making and using the same |
11/15/2007 | US20070264202 Pharmaceutical Composition Comprising an Isomer of Betamimetic Agent and an Anti-Cholinergic Agent |
11/15/2007 | US20070264199 Magnetic nanoparticle composition and methods for using the same |
11/15/2007 | US20070264198 Tumor necrosis agent |
11/15/2007 | US20070264194 Peptides That Bind To Atherosclerotic Lesions |
11/15/2007 | US20070264175 Method And Process For Controlling The Temperature, Pressure-And Density Profiles In Dense Fluid Processes |
11/15/2007 | US20070261695 Sublingual fentanyl spray |
11/15/2007 | DE202004021381U1 Salz einer Sulfonsäure mit Clopidogrel und dessen Verwendung zur Herstellung pharmazeutischer Formulierungen Salt of a sulfonic acid with clopidogrel and its use for the preparation of pharmaceutical formulations |
11/15/2007 | DE19544507B4 Cyclosporin enthaltende Präparate Cyclosporin-containing preparations |
11/15/2007 | DE102006021016A1 Chemically activatable capsule for continuity check and treatment of intestinal tract, comprises interior covering with opposite discharge openings and with a filling from granulates, powder, gel or liquid, and outer covering |
11/15/2007 | CA2651696A1 Modified release tablets comprising tramadol |
11/15/2007 | CA2651596A1 Percutaneous absorption preparations of antidementia drugs |
11/15/2007 | CA2651343A1 A pressure sensitive adhesive composition comprising cross-linked polyalkylene oxide and water absorbent hydrophilic agents |
11/15/2007 | CA2651300A1 A sustained-release intraocular implant comprising a vasoactive agent |
11/15/2007 | CA2651138A1 Pharmaceutical composition |
11/15/2007 | CA2650580A1 A method for delivering a human chorionic gonadotropin (hcg) vaccine for long-acting antibody production |
11/15/2007 | CA2650101A1 Solid dosage formulations |
11/15/2007 | CA2649946A1 New sterilized parenteral formulation |
11/15/2007 | CA2649922A1 Dpp iv inhibitor formulations |
11/15/2007 | CA2649902A1 Spherical microcapsules comprising glp-1 peptides, their production and use |
11/15/2007 | CA2649870A1 Drug release from nanoparticle-coated capsules |
11/15/2007 | CA2649848A1 Heated roller compaction process for making pharmaceutical compositions |
11/14/2007 | EP1854807A1 Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative |
11/14/2007 | EP1854794A1 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
11/14/2007 | EP1854471A1 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
11/14/2007 | EP1854463A1 Release-control composition |
11/14/2007 | EP1854462A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
11/14/2007 | EP1854460A1 External plaster containing flurbiprofen |
11/14/2007 | EP1854457A1 Treated film strips |
11/14/2007 | EP1854456A1 Pressure-sensitive adhesive base and medical adhesive patch including the pressure-sensitive adhesive base |
11/14/2007 | EP1854455A1 Spherical microcapsules comprising GLP-1 peptides, their production and use |